EU Panel Backs Tesaro Cancer Drug

Sep 18, 2017

Reuters

A European Medicines Agency (EMA) panel recommended the approval of Massachusetts-based Tesaro’s niraparib, for the treatment of recurrent ovarian cancer.

The drug, marketed as Zejula, was approved in the United States in March.

The panel’s opinion will be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union. If approved, Zejula will be the first oral, once-daily poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor approved in Europe for use in patients regardless of BRCA mutation or biomarker status.

Read the Reuters coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments